Rationale: Sialylation by α2,3-sialyltransferases has been shown to be a crucial glycosylation step in the generation of functional selectin ligands. Recent evidence suggests that sialylation also affects the binding of chemokines to their corresponding receptor.
G lycosyltransferases are involved in the generation of functional selectin ligands, mediating leukocyte rolling on inflamed endothelium. 1 Mice deficient of α2,3-sialyltransferase IV (St3Gal4) displayed a partially impaired E-selectin ligand function and an almost complete lack of L-selectin-dependent leukocyte rolling on tumor necrosis factor-α (Tnfα)-exposed cremaster muscle venules. [2] [3] [4] More recently, also leukocyte arrest by the chemokine receptor Cxcr2 was shown to depend on ST3Gal-IV-mediated sialylation, because St3Gal4 −/− mice displayed decreased leukocyte adhesion to inflamed microvessels on stimulation with the Cxcr2 ligands Cxcl1 or Cxcl8. 5 In line, human CCR5 requires the attachment of sialic acid-carrying O-glycans for binding of its chemokine ligands CCL3 and CCL4 and subsequent receptor activation, as shown by a combination of sialidase treatment and CCR5 mutants in which the putative binding sites for sialylated O-glycans were exchanged. 6 Because the chemokine receptors Ccr1 and Ccr5 (with high-affinity ligand Ccl5) and Ccr2 (binding Ccl2) were previously shown to be important in myeloid cell recruitment during inflammation, [7] [8] [9] we investigated the role of ST3Gal-IV in Ccl5-and Ccl2-mediated leukocyte arrest on inflamed endothelium and its effect on atherosclerosis using St3Gal4deficient mice.
Methods
Detailed methods are provided in the Online Data Supplement. Throughout the article, the letter format of all gene and protein notations was chosen to conform with internationally agreed gene/protein nomenclature guidelines: all letters of human genes/proteins are in uppercase, whereas for mouse genes/proteins, only the first letter is in uppercase and the remaining letters are in lowercase. Gene names are in italics.
Atherosclerosis Study
St3Gal4 −/− mice 10 were crossed with Apoe −/− mice and received a high-fat diet for 12 weeks. Size and cellular composition of atherosclerotic lesions were assessed by histology and immunofluorescence.
Study of Monocytes and Neutrophils
Primary monocytes and neutrophils were isolated from bone marrow with specific cell separation kits according to the manufacturer's protocol and were used for chemokine-binding assays, flow chamber adhesion experiments, and ex vivo perfusion of mouse carotid arteries. Integrin activation assays and chemokine-binding assays were performed using whole blood, and neutrophils and monocytes were distinguished using specific fluorescent labeling and flow cytometry.
Results

St3Gal4 −/− Monocytes and Neutrophils Show a Reduced Integrin Activation and Flow Arrest Upon Ccl5 Stimulation
Integrin activation is crucial for leukocyte arrest, enabling an efficient interaction with integrin ligands exposed on the endothelium. Interestingly, Ccl5-induced binding of the integrin ligands Icam1 and Vcam1 was significantly reduced in St3Gal4 −/− classical monocytes and neutrophils ( Figure 1A and 1B), which was associated with a significantly decreased ability of Ccl5 to trigger the arrest of St3Gal4 −/− monocytes and neutrophils on Tnfα-activated, SV40-transformed mouse endothelial cells under flow ( Figure 1C ). Also, St3Gal4-deficient mice showed a significant decrease in the accumulation of monocytes and neutrophils in the peritoneal cavity 4 hours after intraperitoneal injection of Ccl5 ( Figure 1D ). Binding of Ccl5 to St3Gal4 −/− myeloid cells was reduced by 30% to 40% (Online Figure IA Figure II) . Furthermore, enzymatic removal of sialic acids using sialidase treatment decreased Ccl5 binding to monocytes and neutrophils by 55% to 80% (Online Figure  IB) and seemed associated with reduced interaction of Ccl5 with both Ccr5 and Ccr1 as shown by sialidase treatment of Ccr1 −/− and Ccr5 −/− myeloid cells, respectively (Online Figure  III) . Together, these data indicate that sialylation by ST3Gal-IV and probably other sialyltransferases improve Ccl5 binding, with ST3Gal-IV-mediated sialylation enabling efficient Ccl5-induced integrin activation and myeloid cell arrest.
In contrast, St3Gal4 deficiency did not affect Ccl2-induced integrin activation or flow arrest of neutrophils and could only significantly reduce the binding of Vcam1 but not Icam1 to Ccl2-triggered monocytes. Correspondingly, Ccl2-induced arrest of St3Gal4 −/− monocytes was only marginally reduced compared with wild-type monocytes, which showed a significantly increased binding upon Ccl2 treatment ( Figure 1A and 1B; Online Figure IVA ). Also, no differences were observed in Ccl2 binding to St3Gal4 −/− versus St3Gal4 +/+ myeloid cells or in the expression of Ccl2 chemokine receptor Ccr2 (Online Figures IVB and II) . Thus, these data imply that not all chemokines are equally influenced by ST3Gal-IV.
To unravel whether endothelial ST3Gal-IV also affects Ccl5induced myeloid cell arrest, we performed ex vivo perfusion assays with mounted and pressurized Tnfα-activated carotid arteries from St3Gal4 +/+ and St3Gal4 −/− mice. Pretreatment of wild-type leukocytes with Ccl5 before perfusion increased their adhesion on the endothelium of both wild-type as St3Gal4 −/− arteries (Figure 2A and 2B, left panels). In contrast, Ccl5 pretreatment of St3Gal4 −/− leukocytes did not enhance their arrest on either St3Gal4 +/+ or St3Gal4 −/− carotid arteries ( Figure 2A and 2B, right), indicating that ST3Gal-IV on leukocytes, but not endothelial cells, enables Ccl5-triggered leukocyte arrest on inflamed endothelium. A role for ST3Gal-IV in inflammatory cell arrest was further confirmed in vivo by the use of intravital fluorescence microscopy of the carotid artery. St3Gal4 −/− mice showed a dramatic reduction in adherent rhodamine 6G-labeled leukocytes (Online Figure V) , despite comparable WBC counts (4.3±2.3 versus 3.5±2.2×10 3 leukocytes/μL blood for St3Gal4 +/+ and St3Gal4 −/− , respectively). A decreased arrest was observed for both neutrophils (CD11b + , Ly6G + ) and classical monocytes (CD11b + , Ly6C + ) based on intravenous labeling with antibodies to CD11b, Ly6G, and Ly6C ( Figure 2C and 2D).
St3Gal4 Deficiency Reduces Atherosclerotic Lesion Size and Myeloid Cell Influx in Mice
As continuous leukocyte adhesion and influx drive atherosclerotic lesion development, 11 we examined a potential role of ST3Gal-IV in atherosclerosis using St3Gal4 −/− Apoe −/− and St3Gal4 +/+ Apoe −/− mice on high-fat diet for 12 weeks. Despite comparable leukocyte subpopulations and only small differences in lipid levels between knock-out and wild-type mice (Online Table) , aortic arches, roots, and thoracoabdominal aortas of St3Gal4 −/− Apoe −/− mice displayed a dramatic reduction in plaque development ( Figure 3A and 3B; Online Figure  VI ). Macrophage and neutrophil numbers in St3Gal4 −/− Apoe −/− aortic root lesions were significantly reduced ( Figure 4A ), whereas the number of smooth muscle cells was not altered ( Figure 4B ). Furthermore, plaque staging of aortic arches and roots according to Virmani et al 12 displayed an initial lesion phenotype in St3Gal4 −/− Apoe −/− mice, characterized by 90% initial xanthomas in arches and 70% initial xanthomas and pathological intima thickening in the roots of these mice. In contrast, plaques in wild-type mice showed a very advanced lesion type, mainly represented by fibrous cap atheromas and fibrocalcification in both arches and roots ( Figure 4C ). In line, the necrotic core area and the accumulation of TUNEL + cells were significantly diminished in atherosclerotic plaques of St3Gal4 −/− Apoe −/− mice ( Figure 4D ).
Interestingly, immunofluorescent staining of initial versus advanced human lesions revealed increased CCL5 levels in
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ST3Gal-IV α2,3-sialyltransferase IV TNFα tumor necrosis factor-α advanced compared with initial plaques (Online Figure VII) . In line, the smaller root lesions of St3Gal4 −/− Apoe −/− mice displayed reduced Ccl5 staining compared with controls (Online Figure VIII) , although Ccl5 serum levels were not significantly changed (Online Figure IX) .
Discussion
This study reveals that the sialyltransferase ST3Gal-IV enables Ccl5-triggered arrest of monocytes and neutrophils on inflamed endothelium. St3Gal4 −/− leukocytes showed a significant reduction in Ccl5 binding and Ccl5-induced integrin activation despite comparable expression of Ccl5 chemokine receptors. This suggests that sialylation facilitates efficient Ccl5 binding through favorable conformational changes in Ccl5 receptors, or through enforced electrostatic interactions of basic chemokine residues with negatively charged sialic acids attached to the chemokine receptors. 6 The contribution of sialylation to efficient Ccl5 binding is supported by the reduction in Ccl5 binding on sialidase treatment, which we observed for both Ccr1 −/− and Ccr5 −/− leukocytes and by a previous report demonstrating human CCR5 to require N-terminal sialylation for efficient chemokine binding. 6 Comparably, St3Gal4 deficiency in leukocytes was previously shown to reduce Cxcl8 binding to Cxcr2 and to impair Cxcl1/Cxcr2-triggered neutrophil arrest. 5 Nonetheless, ST3Gal-IV-mediated sialylation does not seem to be a general requirement for efficient chemokine functioning, because Ccl2-triggered leukocyte arrest was not significantly affected by St3Gal4 deficiency. Circulating monocytes and neutrophils adhere to and accumulate in atherosclerotic vessels, where they crucially contribute to atherogenesis. 11 The recruitment of classical monocytes into atherosclerotic lesions requires Ccr1 9 and Ccr5, 7, 9 whereas the precise role of Ccr2 7, 9, 13 and Cx3cr1 7,9 in monocyte incorporation into lesions has recently been debated. The observed reduction in lesion size in Cx3cr1 −/− Apoe −/− mice [14] [15] [16] may depend on the role of Cx3cr1 in monocyte and macrophage survival, 16 rather than on a direct role of Cx3cr1 in monocyte recruitment into atherosclerotic plaques. 9 Similarly, although the reduced atherosclerotic lesion size in Ccr2 −/− Apoe −/− mice 14, 17 and Ccr2 −/− bone marrow chimeras 18 clearly indicates an important role for Ccr2 in atherosclerosis, the specific role of Ccr2 in the incorporation of circulating monocytes into atherosclerotic arteries requires further investigation. Contradictory findings have been reported on such direct involvement of Ccr2 in lesional monocyte accumulation, 9, 13 suggesting that the proatherogenic role of Ccr2 may rather be related to a crucial role for the Ccl2/Ccr2 axis in the mobilization of monocytes from the bone marrow in inflammatory and atherosclerotic conditions. 9, 15, [19] [20] [21] [22] Compared with monocytes, neutrophils infiltrate atherosclerotic arteries primarily through Cxcr2, Ccr1, Ccr2, and Ccr5. 8 Thus, the importance of ST3Gal-IV in mediating myeloid cell arrest in response to Ccl5 and Cxcl1/Cxcl8, 5 representing high-affinity ligands for Ccr1 and Ccr5, and for Cxcr2, respectively, could explain why St3Gal4-deficient mice display a severely reduced leukocyte arrest on inflamed endothelium and an associated decrease in accumulating macrophages and neutrophils in atherosclerotic vessels. The previous finding that blocking only Ccl5 reduces the arrest of perfused monocytes on atherosclerotic endothelium by ≈50% 23 further supports the importance of ST3Gal-IV in atherogenic myeloid cell accumulation. Furthermore, the requirement of leukocytic ST3Gal-IV for the generation of functional selectin ligands 2-4 may additionally contribute to reduced leukocyte rolling and arrest in St3Gal4 −/− mice.
Interestingly, atherosclerotic lesion size was previously shown to be strongly correlated with the number of circulating monocytes, displaying ≈90% reduction in atherosclerosis when circulating monocyte numbers were reduced with comparable extent. 22 Thus, the arrest and infiltration of circulating monocytes are crucial in determining the lesion size, implying that the severely reduced leukocyte arrest in St3Gal4 −/− mice could, to a great extent, explain their drastic reduction in atherosclerosis. In addition, the less advanced plaque phenotype combined with a lower platelet count on St3Gal4 deficiency 10 could underlie the decreased Ccl5 levels in atherosclerotic vessels of St3Gal4 −/ − Apoe −/− mice, which may further add to the reduction in leukocyte recruitment and atherosclerosis progression. Also, it is possible that reduced Ccl5-induced activation of myeloid cells, as displayed by decreased integrin activation, further contributes to reduced atherogenesis in St3Gal4 −/− Apoe −/− mice. However, further studies are required to pinpoint the exact role of Ccl5 in the atherogenic functions of monocytes and neutrophils, before being able to address the effect of ST3Gal-IV in this context. In addition, the role of endothelial St3Gal4 in inflammation remains unclear. Although our in vitro data revealed a comparable Ccl5-triggered leukocyte adhesion to St3Gal4 −/− versus St3Gal +/+ carotids after 4 hours of Tnfα stimulation, further studies are required to address the specific role of St3Gal4 in endothelial activation and in leukocyte adhesion to chronically inflamed endothelium in more detail in vivo. It is not excluded that St3Gal4 deficiency in vascular cells further contributes to the drastic reduction in atherosclerosis observed in this study.
Altogether, our data point toward an important contribution of ST3Gal-IV in efficient leukocyte recruitment and arrest under inflammatory conditions. Hence, targeting sialylation in atherosclerosis, for example by specific inhibitors of ST3Gal-IV, might be a new promising therapeutic approach.
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